A multicenter, double-blind, randomized study in patients with gastric cancer undergoing postoperative adjuvant chemotherapy
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 21 Mar 2017 Status changed from not yet recruiting to recruiting.
- 05 Jan 2017 Planned initiation date changed from 1 Apr 2016 to 1 Jan 2017.
- 25 Jun 2016 New trial record